We are live on ! Find out more
AXDX

Accelerate Diagnostics

Delisted

AXDX was delisted on the 14th of May, 2025.

72 hedge funds and large institutions have $18M invested in Accelerate Diagnostics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 21 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% less funds holding

Funds holding: 8472 (-12)

29% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 21

56% less capital invested

Capital invested by funds: $41.2M → $18M (-$23.2M)

63% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 16

65% less call options, than puts

Call options by funds: $52K | Put options by funds: $148K

100% less funds holding in top 10

Funds holding in top 10: 30 (-3)

Holders
72
Holders Change
-12
Holders Change %
-14.29%
% of All Funds
1.16%
Holding in Top 10
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
New
6
Increased
15
Reduced
21
Closed
16
Calls
$52K
Puts
$148K
Net Calls
-$96K
Net Calls Change
+$940K

AXDX Hedge Fund Activity: Q4 2022 in Review

72 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2022, worth a combined $18M — down 56% from $41.2M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AXDX and 6 opened new positions — a net loss of 10 holders — while 21 trimmed existing stakes and 15 added.

The largest buyer was Griffin Asset Management, adding an estimated $1.38M. The largest seller was 1492 Capital Management, exiting entirely with an estimated $684K sold.

  • 72 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2022, down from 84 in Q3 2022.
  • Funds reported $18M of Accelerate Diagnostics stock for Q4 2022, down 56% quarter-over-quarter.
  • 6 funds opened new Accelerate Diagnostics positions in Q4 2022 and 16 closed out, a net change of -10 holders.
  • The largest Accelerate Diagnostics buyer in Q4 2022 was Griffin Asset Management, an estimated $1.38M added.
  • The largest Accelerate Diagnostics seller in Q4 2022 was 1492 Capital Management, an estimated $684K sold.

Based on aggregated 13F filings for Q4 2022.